Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Progress in the management of IPF-related acute exacerbations: a goal for patients, respirologists and intensivists

François Vincent, Hilario Nunes, Stéphane Gaudry
European Respiratory Journal 2018 51: 1702419; DOI: 10.1183/13993003.02419-2017
François Vincent
1Réanimation polyvalente, Groupe Hospitalier Intercommunal Le-Raincy Montfermeil, Montfermeil, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: frncsvncnt@aol.com
Hilario Nunes
2Service de Pneumologie, Hôpital Avicenne, Assistance Publique - Hôpitaux de Paris, Bobigny, France
3Université Paris 13, Sorbonne Paris Cité, EA2363 ‘Hypoxie et poumon’, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphane Gaudry
4Service de Réanimation Médico-Chirurgicale, Hôpital Louis Mourier, Assistance Publique - Hôpitaux de Paris, Colombes, France
5Epidémiologie Clinique et Évaluation Économique Appliqué aux Populations Vulnérables (ECEVE), UMR 1123, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

IPF-related acute exacerbations: further research needed http://ow.ly/CB3W30hzYNq

To the Editor:

We read with interest the illuminating review on the pharmacological management of idiopathic pulmonary fibrosis (IPF) recently published in the European Respiratory Journal [1]. Raghu [1] did not detail the pharmacological management of acute exacerbations (AEs). AEs often lead to the question of whether to transfer the patient to the intensive care unit (ICU) for respiratory support, whether this is invasive mechanical ventilation (IMV) or not, and to the choice of adequate pharmacological agent(s) [2]. This is a critical issue for respirologists and intensivists as it is estimated that ∼3 million patients suffer from this disease worldwide [3]. When making the decision of whether to transfer to the ICU, it should be kept in mind that ≤46% of IPF-related deaths are preceded by an AE, with the majority of patients dying within the first month and most of the remaining within a year [2, 4].

The 2011 guidelines from the American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) suggested that IMV might only be reasonable in a minority of patients (weak recommendation, low-quality evidence) [5]. This point was not discussed in the updates published in 2015 [6]. French experts published their recommendations in 2017 [7]. ICU management in a patient with IPF-related AEs appears to be justified when there is a pulmonary transplant, when a reversible cause of exacerbation has been identified, or if the research has not been carried out [7]. It should only be used after discussion with the patients and their relatives (ideally in advance).

The identification of patients who can best benefit from admission to the ICU remains a challenge. The Glasgow Prognostic Score was recently demonstrated to be advantageous in the classification of patients with IPF-related AEs into three disease stages with distinct mortality risk over 1–3 years [8]. Its usefulness in the decision to transfer the patient to the ICU requires validation in prospective cohorts performed in the era of new pharmacological treatments described by Raghu [1].

The data on the symptomatic management of IPF-related AEs (i.e. respiratory support) were recently reviewed by Kondoh et al. [2]. Only four out of five studies published since 2008 included patients in the ICU (182 patients). Data on oxygenation with “new” techniques are lacking. Humidified high-flow nasal cannula oxygen could perhaps be used for long periods, possibly when waiting for lung transplantation [9]. Recent findings suggest that noninvasive ventilation failure could be deleterious as it increases the risk of ventilator-induced lung injury [10]. Extracorporeal oxygenation seems to be available to patients who are waiting for an impending lung transplant [11]. These only detail the supportive care and not the medical advances described by Raghu [1], which are, in our opinion, fundamental.

As briefly discussed, research continues in the pharmacological management of IPF-related AEs [1]. It still typically includes high-dose corticosteroids and/or immunosuppressant and broad-spectrum antibiotics, despite the scarcity of data supporting the usefulness of these therapies [2]. A placebo-controlled randomised phase III trial evaluating the efficacy of cyclophosphamide in conjunction with corticosteroids in IPF-related AEs was recently approved in France (EXAFIP; registered at ClinicalTrials.gov with the identifier number NCT02460588). A number of other novel therapeutic approaches (nintedanib, pirfenidone, polymyxin B direct haemoperfusion, thrombomodulin, rituximab, plasma exchange, intravenous immunoglobulin) have been evaluated or are still being evaluated; however, preliminary results are disappointing or are based on too small series [2]. We believe that Raghu [1] emphasises above all the lack of relevant data on the pharmacological management of IPF-related AEs and the need for further studies.

Footnotes

  • Conflict of interest: None declared.

  • Received November 23, 2017.
  • Accepted November 29, 2017.
  • Copyright ©ERS 2018

References

  1. ↵
    1. Raghu G
    . Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J 2017; 50: 1701209.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Kondoh Y,
    2. Cottin V,
    3. Brown KK
    . Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir Rev 2017; 26: 170050.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Martinez FJ,
    2. Collard HR,
    3. Pardo A, et al.
    Idiopathic pulmonary fibrosis. Nat Rev Dis Primers 2017; 3: 17074.
    OpenUrl
  4. ↵
    1. Spagnolo P,
    2. Wuyts W
    . Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2017; 23: 411–417.
    OpenUrl
  5. ↵
    1. Raghu G,
    2. Collard HR,
    3. Egan JJ, et al.
    An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Raghu G G.,
    2. Rochwerg BB,
    3. Zhang YY, et al.
    An official ATS/ERS/JRS/ALAT clinical practice guidelines: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192: e3–e19.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Cottin V,
    2. Crestani B,
    3. Cadranel J, et al.
    French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2017 update. Full-length version. Rev Mal Respir 2017; 34: 900–968.
    OpenUrl
  8. ↵
    1. Kang HS,
    2. Cho KW,
    3. Kwon SS, et al.
    Prognostic significance of Glasgow prognostic score in patients with acute exacerbation of idiopathic pulmonary fibrosis. Respirology 2018; 23: 206–212.
  9. ↵
    1. Boyer A,
    2. Vargas F,
    3. Delacre M, et al.
    Prognostic impact of high-flow nasal cannula oxygen supply in an ICU patient with pulmonary fibrosis complicated by acute respiratory failure. Intensive Care Med 2011; 37: 558–559.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Vianello A,
    2. Arcaro G,
    3. Battistella L, et al.
    Noninvasive ventilation in the event of acute respiratory failure in patients with idiopathic pulmonary fibrosis. J Crit Care 2014; 29: 562–567.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Trudzinski FC,
    2. Kaestner F,
    3. Schafers HJ, et al.
    Outcome of patients with interstitial lung disease treated with extracorporeal membrane oxygenation for acute respiratory failure. Am J Respir Crit Care Med 2016; 193: 527–533.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 51 Issue 2 Table of Contents
European Respiratory Journal: 51 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Progress in the management of IPF-related acute exacerbations: a goal for patients, respirologists and intensivists
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Progress in the management of IPF-related acute exacerbations: a goal for patients, respirologists and intensivists
François Vincent, Hilario Nunes, Stéphane Gaudry
European Respiratory Journal Feb 2018, 51 (2) 1702419; DOI: 10.1183/13993003.02419-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Progress in the management of IPF-related acute exacerbations: a goal for patients, respirologists and intensivists
François Vincent, Hilario Nunes, Stéphane Gaudry
European Respiratory Journal Feb 2018, 51 (2) 1702419; DOI: 10.1183/13993003.02419-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Rifapentine access in Europe: concerns over key TB treatment
  • P. aeruginosa membrane vesicles cause endothelial barrier failure
  • Mortality after admission with pneumonia higher than after admission with COPD exacerbation
Show more Agora

Correspondence

  • Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside
  • Liver cancer in severe alpha-1 antitrypsin deficiency: Who is at risk?
  • Cancer risk in severe alpha-1-antitrypsin deficiency - the importance of the early identification
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society